NA
ANIP icon

Navellier & Associates’s ANI Pharmaceuticals ANIP Stock Holding History

Navellier & Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,025
Closed -$317K – 227
2015
Q3 		$317K Sell
8,025
-2,929
-27% -$167K 0.03% 211
2015
Q2 		$680K Buy
10,954
+605
+6% +$36K 0.06% 158
2015
Q1 		$647K Buy
+10,349
New +$630K 0.06% 158

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Navellier & Associates's ANIP Position: Q4 2015 in Review

Navellier & Associates sold out of ANI Pharmaceuticals (ANIP) in Q4 2015, closing a stake of 8,025 shares — an estimated $317K sold.

Navellier & Associates first reported a position in ANIP in Q1 2015 and held it in 3 quarters. The position peaked at $680K in Q2 2015. 123 funds tracked by Wall St. Rank hold ANIP as of Q4 2015.

  • Navellier & Associates reported no remaining ANI Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Navellier & Associates sold 8,025 ANI Pharmaceuticals shares in Q4 2015, an estimated $317K.
  • Navellier & Associates first reported a position in ANI Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Navellier & Associates's ANI Pharmaceuticals position peaked at $680K in Q2 2015.
  • 123 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2015.

Based on Navellier & Associates's 13F filing for Q4 2015, filed 10 Feb 2016.